Back to Browse Journals » International Journal of Nanomedicine » Volume 7
Design of near-infrared fluorescent bioactive conjugated functional iron oxide nanoparticles for optical detection of colon cancer
Authors Corem-Salkmon E, Perlstein B, Margel S
Received 9 May 2012
Accepted for publication 21 June 2012
Published 19 October 2012 Volume 2012:7 Pages 5517—5527
DOI https://doi.org/10.2147/IJN.S33710
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Enav Corem-Salkmon, Benny Perlstein, Shlomo Margel
The Institute of Nanotechnology and Advanced Materials, Department of Chemistry, Bar-Ilan University, Ramat-Gan, Israel
Background: Colon cancer is one of the major causes of death in the Western world. Early detection significantly improves long-term survival for patients with the disease. Near-infrared (NIR) fluorescent nanoparticles hold great promise as contrast agents for tumor detection. NIR offers several advantages for bioimaging compared with fluorescence in the visible spectrum, ie, lower autofluorescence of biological tissues, lower absorbance, and consequently deeper penetration into biomatrices.
Methods and results: NIR fluorescent iron oxide nanoparticles with a narrow size distribution were prepared by nucleation, followed by controlled growth of thin iron oxide films onto cyanine NIR dye conjugated gelatin-iron oxide nuclei. For functionalization, and in order to increase the NIR fluorescence intensity, the NIR fluorescent iron oxide nanoparticles obtained were coated with human serum albumin containing cyanine NIR dye. Leakage of the NIR dye from these nanoparticles into phosphate-buffered saline solution containing 4% albumin was not detected. The work presented here is a feasibility study to test the suitability of iron oxide-human serum albumin NIR fluorescent nanoparticles for optical detection of colon cancer. It demonstrates that encapsulation of NIR fluorescent dye within these nanoparticles significantly reduces photobleaching of the dye. Tumor-targeting ligands, peanut agglutinin and anticarcinoembryonic antigen antibodies (αCEA), were covalently conjugated with the NIR fluorescent iron oxide-human serum albumin nanoparticles via a poly(ethylene glycol) spacer. Specific colon tumor detection was demonstrated in chicken embryo and mouse models for both nonconjugated and the peanut agglutinin-conjugated or αCEA-conjugated NIR fluorescent iron oxide-human serum albumin nanoparticles.
Conclusion: Conjugation of peanut agglutinin or αCEA to the nanoparticles significantly increased the fluorescence intensity of the tagged colon tumor tissues relative to the nonconjugated nanoparticles.
Keywords: near-infrared fluorescence, iron oxide nanoparticles, optical imaging, chorioallantoic membrane assay, colon cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Other articles by this author:
Synthesis and characterization of bioactive conjugated near-infrared fluorescent proteinoid-poly(L-lactic acid) hollow nanoparticles for optical detection of colon cancer
Kolitz-Domb M, Corem-Salkmon E, Grinberg I, Margel S
International Journal of Nanomedicine 2014, 9:5041-5053
Published Date: 31 October 2014
Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils
Skaat H, Corem-Slakmon E, Grinberg I, Last D, Goez D, Mardor Y, Margel S
International Journal of Nanomedicine 2013, 8:4063-4076
Published Date: 29 October 2013
Readers of this article also read:
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus
Jeong HR, An SSA
Clinical Interventions in Aging 2015, 10:1873-1879
Published Date: 19 November 2015
Emerging and future therapies for hemophilia
Carr ME, Tortella BJ
Journal of Blood Medicine 2015, 6:245-255
Published Date: 3 September 2015
A new recombinant factor VIII: from genetics to clinical use
Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H
Drug Design, Development and Therapy 2015, 9:3817-3819
Published Date: 23 July 2015
Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders
Cai Y, An SSA, Kim SY
Clinical Interventions in Aging 2015, 10:1163-1172
Published Date: 14 July 2015
Acquired hemophilia A: emerging treatment options
Janbain M, Leissinger CA, Kruse-Jarres R
Journal of Blood Medicine 2015, 6:143-150
Published Date: 8 May 2015
A new recombinant factor VIII: from genetics to clinical use
Santagostino E
Drug Design, Development and Therapy 2014, 8:2507-2515
Published Date: 12 December 2014
Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A
Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S
Neuropsychiatric Disease and Treatment 2014, 10:865-867
Published Date: 16 May 2014
Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy
Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS
International Journal of Nanomedicine 2012, 7:4077-4088
Published Date: 27 July 2012
A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice
Shen CC, Wang CC, Liao MH, Jan TR
International Journal of Nanomedicine 2011, 6:1229-1235
Published Date: 20 June 2011
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
International Journal of Nanomedicine 2010, 5:581-591
Published Date: 6 August 2010
